Parkinson DiseaseNCT06880068
Reliability and Validity of DIDA-Q in Parkinson's Disease
An observational study of Parkinson Disease, run by Marmara University at 1 site in Turkey (Türkiye).
Trial summary
The aim of our study is to investigate the validity and reliability of the Dual Task Impact on Daily-living Activities (DIDA-Q) to assess the degree of difficulty felt when performing dual tasks during activities of daily living in patients with Parkinson's disease. Read more about this study
- Who is it for?
- Ages 39 to 85 years
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Dual Task Impact on Daily-living Activities Questionnaire
- How many people
- 95 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 13 Jan 2024to 10 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 39 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who diagnosed with Parkinson's disease were included.
Who may be able to join
- Diagnosed with Idiopathic Parkinson's Disease according to UK Brain Bank criteria
- Walking at least 10 metres without an assistive device
- To have the cognitive capability to understand and answer the questions asked in the scale
Who cannot join
- Having any neurological disease other than idiopathic Parkinson's Disease
- The person has an orthopaedic or cardiopulmonary disease that affects walking
- Severe hearing-visual impairment
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Istanbul University, Faculty of Medicine
Istanbul, Çapa
About this study
Official title: Validity and Reliability of the Dual Task Impact on Daily Living Questionnaire in Patients with Parkinson's Disease
The aim of our study is to investigate the validity and reliability of the Dual Task Impact on Daily-living Activities (DIDA-Q) to assess the degree of difficulty felt when performing dual tasks during activities of daily living in patients with Parkinson's disease. In our study, the validity and reliability of a questionnaire to assess the degree of difficulty felt while performing dual tasks during activities of daily living in Parkinson's Disease will be examined for the first time. The study will include 95 participants with Hoehn-Yahr Stage 1-3, diagnosed with Idiopathic Parkinson's Disease and able to walk 10 metres without an assistive device.
Read the detailed description
Dual task ability is defined as the ability to perform two activities simultaneously . It is known that the ability to perform a motor or cognitive secondary activity at the same time during walking (talking to a person next to you while walking or carrying objects while walking) leads to gait and balance problems of different severity depending on the type of secondary task in Parkinson's Disease (PD). When patients with Parkinson's Disease (pwPD) are exposed to dual-task walking, their walking speed and length of stride decrease, and the frequency of freezing phenomena during walking increases. Consequently the risk of falling increase during activities of daily living. Individuals often perform dual tasks while performing activities of daily living because of the nature of the tasks' requirements. Therefore, it has become important to evaluate dual task performance in order to create the right treatment plan in the field of neurological physiotherapy and rehabilitation. Although dual task performance is evaluated with different formulae in the literature, the number of scales evaluating the level of difficulty perceived by the patient during the performance of activities of daily living under dual task is limited. The validity of the existing scales for PD has not been studied. The Dual-task Impact on Daily-living Activities Questionnaire (DIDA-Q) is a patient-reported questionnaire developed to assess the degree of difficulty perceived when performing dual tasks during activities of daily living.
- Conditions
- Parkinson Disease
- Being tested
- Dual Task Impact on Daily-living Activities Questionnaire
- Keywords
- Parkinson's Disease, Dual-task Assessment, Neurological Physiotherapy
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dual Task Impact on Daily-living Activities QuestionnaireDiagnostic test
This questionnaire makes us assess dual-task performance while performing daily-living activities.
What is being measured
The primary outcome is the main question the study is designed to answer.
DIDA-Q
Dual Task Impact on Daily-living Activities Questionnaire, higher scores means bad dual task performance
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2025
- Study start13 Jan 2024
- Primary completion1 Jan 2025
- Study completion10 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Marmara UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 95 participants (actual)
Sponsor and investigators
- Lead sponsor
- Marmara University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06880068
- Sponsor's protocol ID
- MarmaraU-SANLI-ERSOZ-001
- Status last verified
- Jan 2025
- First submitted
- 13 Jan 2025
- Last updated
- 17 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validity and Reliability of the Dual Task Impact on Daily Living Questionnaire in Patients with Parkinson's Disease
- ClinicalTrials.gov ID
- NCT06880068
- Acronym / sponsor ID
- MarmaraU-SANLI-ERSOZ-001
- Conditions
- Parkinson Disease
- Keywords
- Parkinson's Disease, Dual-task Assessment, Neurological Physiotherapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 95 participants (actual)
- Lead sponsor
- Marmara UniversityUniversity, hospital or other
- Study start
- 13 Jan 2024 (actual)
- Primary completion
- 1 Jan 2025 (actual)
- Study completion
- 10 Jan 2025 (actual)
- First posted
- 17 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our study is to investigate the validity and reliability of the Dual Task Impact on Daily-living Activities (DIDA-Q) to assess the degree of difficulty felt when performing dual tasks during activities of daily living in patients with Parkinson's disease. In our study, the validity and reliability of a questionnaire to assess the degree of difficulty felt while performing dual tasks during activities of daily living in Parkinson's Disease will be examined for the first time. The study will include 95 participants with Hoehn-Yahr Stage 1-3, diagnosed with Idiopathic Parkinson's Disease and able to walk 10 metres without an assistive device.
Detailed description
Dual task ability is defined as the ability to perform two activities simultaneously . It is known that the ability to perform a motor or cognitive secondary activity at the same time during walking (talking to a person next to you while walking or carrying objects while walking) leads to gait and balance problems of different severity depending on the type of secondary task in Parkinson's Disease (PD). When patients with Parkinson's Disease (pwPD) are exposed to dual-task walking, their walking speed and length of stride decrease, and the frequency of freezing phenomena during walking increases. Consequently the risk of falling increase during activities of daily living. Individuals often perform dual tasks while performing activities of daily living because of the nature of the tasks' requirements. Therefore, it has become important to evaluate dual task performance in order to create the right treatment plan in the field of neurological physiotherapy and rehabilitation. Although dual task performance is evaluated with different formulae in the literature, the number of scales evaluating the level of difficulty perceived by the patient during the performance of activities of daily living under dual task is limited. The validity of the existing scales for PD has not been studied. The Dual-task Impact on Daily-living Activities Questionnaire (DIDA-Q) is a patient-reported questionnaire developed to assess the degree of difficulty perceived when performing dual tasks during activities of daily living.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 39 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who diagnosed with Parkinson's disease were included.
Key inclusion criteria (3 listed)
- Diagnosed with Idiopathic Parkinson's Disease according to UK Brain Bank criteria
- Walking at least 10 metres without an assistive device
- To have the cognitive capability to understand and answer the questions asked in the scale
Key exclusion criteria (3 listed)
- Having any neurological disease other than idiopathic Parkinson's Disease
- The person has an orthopaedic or cardiopulmonary disease that affects walking
- Severe hearing-visual impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dual Task Impact on Daily-living Activities QuestionnaireThis questionnaire makes us assess dual-task performance while performing daily-living activities. | Diagnostic test | – |
Primary outcome
DIDA-Q
Time frame: 1 week
Dual Task Impact on Daily-living Activities Questionnaire, higher scores means bad dual task performance
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Marmara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DIDA-Q (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2025.